In vitro sulfonation of 7-hydroxycoumarin derivatives in liver cytosol of human and six animal species
Juvonen, R. O., Pentikäinen, O., Huuskonen, J., Timonen, J., Kärkkäinen, O., Heikkinen, A., Fashe, M., & Raunio, H. (2020). In vitro sulfonation of 7-hydroxycoumarin derivatives in liver cytosol of human and six animal species. Xenobiotica, 50(8), 885-893. https://doi.org/10.1080/00498254.2020.1711544
Published in
XenobioticaAuthors
Date
2020Copyright
© 2020 Taylor & Francis
1. Sulfonation is an important high affinity elimination pathway for phenolic compounds.
2. In this study sulfonation of 7-hydroxycoumarin and 13 its derivatives were evaluated in liver cytosols of human and six animal species. 7-hydroxycoumarin and its derivatives are strongly fluorescent, and their sulfate conjugates are nonfluorescent at excitation 405 nm and emission 460 nm. A convenient fluorescence based kinetic assay of sulfonation was established.
3. The sulfonation rate of most of the 7-hydroxycoumarin derivatives was low in liver cytosol of human and pig, whereas it was high with most compounds in dog and intermediate in rat, mouse, rabbit, and sheep. Sulfonation of the 7-hydroxycoumarin derivatives followed Michaelis-Menten kinetics with Km values of 0.1–12 µM, Vmax of 0.005–1.7 µmol/(min * g protein) and intrinsic clearance (Vmax/Km) of 0.004–1.9 L/(min * g cytosolic protein).
4. Fluorescence based measurement of sulfonation of 7-hydroxycoumarin derivatives provides a sensitive and convenient high-throughput assay to determine sulfonation rate in different species and tissues and can be applied to evaluate sulfonation kinetics and inhibition.
...
Publisher
Taylor & FrancisISSN Search the Publication Forum
0049-8254Keywords
Publication in research information system
https://converis.jyu.fi/converis/portal/detail/Publication/34160103
Metadata
Show full item recordCollections
Additional information about funding
This work was supported by the Academy of Finland [grant no. 137589] and by the Sigrid Juselius Foundation [grant no. 4704583]. The dog samples have been provided earlier by the Roche Postdoc Fellowship (RPF) program.License
Related items
Showing items with similar title or keywords.
-
In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs
Juvonen, Risto O.; Heikkinen, Aki T.; Kärkkäinen, Olli; Jehangir, Rabia; Huuskonen, Juhani; Troberg, Johanna; Raunio, Hannu; Pentikäinen, Olli T.; Finel, Moshe (Elsevier BV, 2020)Beagle dog is a standard animal model for evaluating nonclinical pharmacokinetics of new drug candidates. Glucuronidation in intestine and liver is an important first-pass drug metabolic pathway, especially for phenolic ... -
AKR1C3-entsyymin tuotto-, puhdistus- ja kiteytysolosuhteiden optimointi
Keisanen, Anni (2018)Aldo-keto-reduktaasi (AKR) kuuluu oksidoreduktaasin superperheeseen. Ihmisen (Homo sapiens) AKR1C3 (aldo-keto reduktaasi C3) säätelee elimistön hormonituotantoa osallistumalla prostaglandiini- ja steroidisynteeseihin. ... -
Kotkan jalat, leijonan pää : hybridihahmot keskiajan latinankielisessä kuvamagiassa
Ockenström, Lauri (Taidehistorian seura, 2020)Ihmisten ja eläinten risteymät eli hybridit olivat yleinen ja taidehistoriassa laajasti tutkittu keskiaikaisen kuvakulttuurin osa. Oppineen magian alalajin kuvamagian lähteissä esiintyvästä monipuolisesta eläin- ja ... -
Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10
Juvonen, Risto O.; Rauhamäki, Sanna; Kortet, Sami; Niinivehmas, Sanna; Troberg, Johanna; Petsalo, Aleksanteri; Huuskonen, Juhani; Raunio, Hannu; Finel, Moshe; Pentikäinen, Olli (American Chemical Society, 2018)Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the bioavailability of phenolic compounds. UGT1A10 catalyzes glucuronidation reactions in the intestine, but not in the liver. ... -
The effect of experimental conditions on the performance of a small-scale dissolution-permeation model in drug development
Hiidenhovi, Sara (2022)Useimmat uudet lääkeaineet ovat heikosti liukenevia ja lääkeaineen määrä lääkekehityksessä on hyvin rajallinen. Sen vuoksi on tarve löytää uusia liukoisuutta parantavia formulaatioita ja pienen mittakaavan metodeja ja ...